Is There Any Need for Adjusting 131I Activity for the Treatment of High Turnover Graves' Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis
- PMID: 33643485
- PMCID: PMC7881070
- DOI: 10.1007/s13139-020-00674-3
Is There Any Need for Adjusting 131I Activity for the Treatment of High Turnover Graves' Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis
Abstract
Purpose: To compare 131I-therapy outcomes in high turnover and normal turnover Graves' disease patients and predict optimal first 131I activity for high turnover patients.
Methods: Retrospective cohort design (1:2) validated by propensity score analysis. Cohort 1, high turnover (2-h RAIU/24-h RAIU ≥ 1), n = 104, and cohort 2, normal turnover (ratio < 1), n = 208, patients were compared for post 131I outcome. The cure was defined as a combined euthyroid and stable hypothyroid state following 131I treatment. Logistic regression analysis was used for identifying prognostic factors. The propensity score was applied; 77 matched pairs (1:1 ratio) of high and normal turnover patients were selected as a validation set.
Results: First 131I cure rates of 28% in high turnover and 66% in normal turnover groups (p = 0.001) were noted. The therapy cycles (median, 2 vs. 1) and cumulative 131I activity (median, 15 vs. 7 mCi) were required to cure hyperthyroidism in cohort 1 and cohort 2, respectively. Age (> 44 years), higher grade of goitre, and 2-h RAIU (> 37%) were associated with 131I therapy failure. The high turnover patients needed a factor of 1.5-2 times more 131I activity to achieve a similar cure rate compared to the normal turnover patients. The first-dose cure rate was 31% vs. 60% by propensity score analysis (n = 154), no way different (28% vs.66%) from the whole group of 312 patients.
Conclusion: High turnover Graves' disease patients, if administered standard 131I activity, the outcomes shall be poor. To improve the success rate, 131I activity should be increased by 1.5 to 2 times in the high turnover patients.
Supplementary information: The online version contains supplementary material available at 10.1007/s13139-020-00674-3.
Keywords: Graves’ disease; High turnover; Normal turnover; Radioiodine therapy; Turnover.
© Korean Society of Nuclear Medicine 2021.
Conflict of interest statement
Conflict of InterestSaurabh Arora and Chandrasekhar Bal declare that they have no conflict of interest.
Figures


Similar articles
-
Long-term follow-up study of radioiodine treatment of hyperthyroidism.Clin Endocrinol (Oxf). 2004 Nov;61(5):641-8. doi: 10.1111/j.1365-2265.2004.02152.x. Clin Endocrinol (Oxf). 2004. PMID: 15521969
-
The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation.Endocr Connect. 2016 Jan;5(1):34-40. doi: 10.1530/EC-15-0119. Epub 2016 Jan 15. Endocr Connect. 2016. PMID: 26772754 Free PMC article.
-
Efficacy of radioactive iodine treatment of graves' hyperthyroidism using a single calculated 131I dose.Clin Diabetes Endocrinol. 2018 Nov 28;4:20. doi: 10.1186/s40842-018-0071-6. eCollection 2018. Clin Diabetes Endocrinol. 2018. PMID: 30505461 Free PMC article.
-
A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.Thyroid. 2021 Dec;31(12):1829-1838. doi: 10.1089/thy.2021.0302. Thyroid. 2021. PMID: 34598656 Free PMC article.
-
Hyperthyroidism. Current treatment guidelines.Drugs. 1998 Apr;55(4):543-53. doi: 10.2165/00003495-199855040-00005. Drugs. 1998. PMID: 9561343 Review.
Cited by
-
Predictive Factors for the Efficacy of Radioactive Iodine Treatment of Graves' Disease: An Experience From 613 Chinese Patients.Int J Endocrinol. 2024 Nov 8;2024:7535093. doi: 10.1155/2024/7535093. eCollection 2024. Int J Endocrinol. 2024. PMID: 39555247 Free PMC article.
-
Comparison of Thyroid Size-Specific Radioiodine Dose and New Modified Dose Calculation in the Treatment of Graves' Disease.Endocrinol Metab (Seoul). 2024 Oct;39(5):758-766. doi: 10.3803/EnM.2024.1950. Epub 2024 Oct 14. Endocrinol Metab (Seoul). 2024. PMID: 39397513 Free PMC article.
-
The EANM guideline on radioiodine therapy of benign thyroid disease.Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3324-3348. doi: 10.1007/s00259-023-06274-5. Epub 2023 Jul 3. Eur J Nucl Med Mol Imaging. 2023. PMID: 37395802 Free PMC article.
References
-
- Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81:2986–2993. - PubMed
-
- Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1:129–135. - PubMed
-
- de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol. 2009;161:771–777. - PubMed
-
- Jaiswal AK, Bal C, Damle NA, Ballal S, Goswami R, Hari S, et al. Comparison of clinical outcome after a fixed-dose versus dosimetry-based radioiodine treatment of Graves’ disease: results of a randomized controlled trial in Indian population. Indian J Endocrinol Metab. 2014;18:648–654. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources